These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 25534140)
21. The therapeutic potential of GPR119 agonists for type 2 diabetes. Ohishi T; Yoshida S Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451 [TBL] [Abstract][Full Text] [Related]
22. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Ryan GJ; Jobe LJ; Martin R Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288 [TBL] [Abstract][Full Text] [Related]
23. Can targeting SIRT-1 to treat type 2 diabetes be a good strategy? A review. Pulla VK; Battu MB; Alvala M; Sriram D; Yogeeswari P Expert Opin Ther Targets; 2012 Aug; 16(8):819-32. PubMed ID: 22762724 [TBL] [Abstract][Full Text] [Related]
24. Protection of pancreatic beta-cells: is it feasible? Bonora E Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375 [TBL] [Abstract][Full Text] [Related]
29. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. Havale SH; Pal M Bioorg Med Chem; 2009 Mar; 17(5):1783-802. PubMed ID: 19217790 [TBL] [Abstract][Full Text] [Related]
30. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. Johnson JL; Wolf SL; Kabadi UM Arch Intern Med; 1996 Feb; 156(3):259-64. PubMed ID: 8572835 [TBL] [Abstract][Full Text] [Related]
31. The Hot and Potential Targets of Type 2 Diabetes Mellitus Treatment in Recent Decade. Xu Q; Wang L; Luo J; Shi D Curr Drug Targets; 2018; 19(1):55-69. PubMed ID: 28270085 [TBL] [Abstract][Full Text] [Related]
32. [Hypoglycemic treatment of type 2 diabetes]. Thorsby P; Kilhovd B; Sletmo R; Martinsen S; Birkeland KI Tidsskr Nor Laegeforen; 2000 Aug; 120(20):2434-40. PubMed ID: 11475233 [TBL] [Abstract][Full Text] [Related]
33. Examining the safety of PPAR agonists - current trends and future prospects. Bortolini M; Wright MB; Bopst M; Balas B Expert Opin Drug Saf; 2013 Jan; 12(1):65-79. PubMed ID: 23134541 [TBL] [Abstract][Full Text] [Related]
34. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus. Campbell RK Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843 [TBL] [Abstract][Full Text] [Related]
35. Medically minimising the impact of hypoglycaemia in type 2 diabetes: a review. Noh RM; Graveling AJ; Frier BM Expert Opin Pharmacother; 2011 Oct; 12(14):2161-75. PubMed ID: 21668402 [TBL] [Abstract][Full Text] [Related]
37. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight. Pi-Sunyer FX Postgrad Med; 2008 Jul; 120(2):5-17. PubMed ID: 18654064 [TBL] [Abstract][Full Text] [Related]
38. Achieving glycemic control in type 2 diabetes: a practical guide for clinicians on oral hypoglycemics. Willett LL; Albright ES South Med J; 2004 Nov; 97(11):1088-92. PubMed ID: 15586599 [TBL] [Abstract][Full Text] [Related]
39. Advances in the treatment of type 2 diabetes mellitus. Israili ZH Am J Ther; 2011; 18(2):117-52. PubMed ID: 19834322 [TBL] [Abstract][Full Text] [Related]
40. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders. Shah U; Kowalski TJ Vitam Horm; 2010; 84():415-48. PubMed ID: 21094910 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]